| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Wendye Robbins last filed a Form 4 in March 2025, as Director at RAPT. From November 2019 to March 2023, the filings on record show 16 open-market purchases and 0 sales. Wendye Robbins's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Wendye Robbins a middling insider score of 59/100, based on 11 past trades. Over a 12-month horizon, 27.3% of those trades were profitable, with an average 12-month return of -11.8%.
At the last filing, the largest reported position was 6,500 shares of RAPT. Net of sales, the RAPT filings show accumulation of 26,505 shares.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2020 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 1,000 | $16.09 | $16,085.00 | -200.0% | |
| Sep 28, 2020 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 500 | $28.70 | $14,350.00 | +8.3% | |
| Sep 24, 2020 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 600 | $28.80 | $17,279.67 | +11.0% | |
| Jul 24, 2020 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 900 | $22.47 | $20,225.00 | +19.8% | |
| Jul 1, 2020 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 2,600 | $26.01 | $67,632.00 | +133.3% | |
| Nov 4, 2019 | RAPT Rapt Therapeutics, Inc. | Director | Buy | 1,600 | $12.00 | $19,200.00 | New |